|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Important molecular interactions leading to AD neuropathology were described in amyloid cascade and in tau protein function.
|
23553131 |
2013 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Tauopathies such as Alzheimer's disease (AD), Pick's disease (PiD), Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) etc. represent a group of age-related neurodegenerative disorders in which tau protein loses its normal conformation mostly due to hyperphosphorylation and subsequent formation of the aggregates of defined shapes, known as Neurofibrillary Tangles (NFTs).
|
31715291 |
2020 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thermodynamics of the interaction between Alzheimer's disease related tau protein and DNA.
|
25126942 |
2014 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Consistent interaction between GSK3B and MAPT genes in three late-onset AD cohorts was observed, with the GSK3B haplotype (T-T) significantly increasing the risk for AD in individuals with at least one H2 haplotype (odds ratio, 1.68-2.33; p = 0.005-0.036).
|
18991351 |
2008 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mitochondrial dysfunction and oxidative stress play an important role in ageing and have been implicated in several age-related neurodegenerative conditions including Alzheimer's disease (AD) and other tauopathies characterized by the presence of intracellular accumulations of the hyperphosphorylated microtubule-associated protein tau.
|
19942317 |
2011 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The neuropathology of Alzheimer's disease (AD) includes amyloid plaque formation by the amyloid β-protein (Aβ) and intracellular paired helical filament formation by tau protein.
|
27943341 |
2017 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
A key knowledge gap blocking development of effective therapeutics for Alzheimer's disease (AD) is the lack of understanding of how amyloid beta (Aβ) peptide and pathological forms of the tau protein cooperate in causing disease phenotypes.
|
31825838 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The microtubule-associated protein tau, in a hyperphosphorylated form, aggregates into insoluble paired-helical filaments (PHFs) in Alzheimer's disease (AD) and other tauopathies.
|
19459590 |
2009 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Accumulation of hyperphosphorylated tau protein is a histopathological hallmark of Alzheimer's disease (AD) and related tauopathies.
|
28073379 |
2017 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the microtubule-associated protein tau gene have been linked to neurofibrillary tangle (NFT) formation in several neurodegenerative diseases known as tauopathies; however, no tau mutations occur in Alzheimer's disease, although this disease is also characterized by NFT formation and cell death.
|
15930395 |
2005 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
One of the pathological hallmarks of AD is hyperphosphorylated tau protein, which forms neurofibrillary tangles.
|
26923011 |
2016 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
By affirming markers of abnormal Aβ and tau proteins as the essential pathobiological signature of Alzheimer's disease, the Framework tacitly reinforces the amyloid (Aβ) cascade as the leading theory of Alzheimer pathogenesis.
|
30220236 |
2018 |
|
Alzheimer's Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Glycogen synthase kinase 3 (GSK3) has been identified as a promising target for the treatment of Alzheimer's disease (AD), where abnormal activation of this enzyme has been associated with hyperphosphorylation of tau proteins.
|
31792284 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.
|
12428809 |
2002 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The increase in CLU alloforms was most closely associated with increases in both insoluble Aβ42 and tau protein (p = 0.001), supporting its role in AD pathogenesis.
|
31813628 |
2020 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD), the leading cause of dementia worldwide, is characterized by the accumulation of the β-amyloid peptide (Aβ) within the brain along with hyperphosphorylated and cleaved forms of the microtubule-associated protein tau.
|
21456963 |
2011 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Self-assembly of the microtubule-associated protein tau into neurotoxic oligomers, fibrils, and paired helical filaments, and cell-to-cell spreading of these pathological tau species are critical processes underlying the pathogenesis of Alzheimer's disease and other tauopathies.
|
31046227 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Oxidative stress is implicated in the pathogenesis of Alzheimer's disease (AD) and other tauopathies and participates in their development by promoting hyperphosphorylation of microtubule-associated protein tau.
|
28269786 |
2017 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
They include the largely sporadic Alzheimer's disease (AD), progressive supranuclear palsy, corticobasal degeneration, Pick's disease and argyrophilic grain disease, as well as the inherited frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
|
15615642 |
2005 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our study used a specific monoclonal antibody made against Aβ42, which not only reacted strongly with Aβ42, tau protein, and α-synuclein, but also had from weak to strong reactions with 25 different pathogens or their molecules, some of which have been associated with AD.
|
29689721 |
2018 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Brain lesions in Alzheimer's disease (AD) include amyloid plaques made of Aβ peptides and neurofibrillary tangles composed of hyperphosphorylated tau protein with synaptic and neuronal loss and neuroinflammation.
|
30821420 |
2019 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the intracellular accumulation of highly phosphorylated tau protein, the extracellular formation of amyloid plaques and a significant loss of neurons.
|
12923647 |
2003 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aggregation of the microtubule-associated protein tau into paired helical filaments to form neurofibrillary tangles constitutes one of the pathological hallmarks of Alzheimer's disease.
|
24444746 |
2014 |
|
Alzheimer's Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies.
|
27975248 |
2017 |
|
Alzheimer's Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In Alzheimer's disease (AD), the microtubule-associated protein, tau, is compromised in its normal association with microtubules and forms into paired helical filaments (PHF) that are the hallmark cytoskeletal pathology of the disease.
|
12444595 |
2002 |